Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 4:54 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 612 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: iron Clear all

Conditions: Iron Deficiency Anaemia, Iron Deficiency Anemia
Interventions: Iron isomaltoside/ferric derisomaltose, Ferric carboxymaltose; Drug
Lead sponsor: Pharmacosmos A/S; Industry
Eligibility: 18 Years and older
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 16
States / cities: Los Angeles, California • Sacramento, California • Santa Ana, California + 9 more

Conditions: Iron Deficiencies
Interventions: Qualia Iron Version A, Qualia Iron Version B, Placebo; Dietary Supplement
Lead sponsor: Qualia Life Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: Carlsbad, California

Conditions: End Stage Renal Disease
Interventions: Triferic; Drug
Lead sponsor: Rockwell Medical Technologies, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Kalamazoo, Michigan

Conditions: Anemia of Prematurity, Very Low Birth Weight Infant
Interventions: 2mg/kg/day Iron Sulfate, 6 mg/kg/day Iron Sulfate; Drug
Lead sponsor: University of South Florida; Other
Eligibility: 1 Day to 6 Months
Enrollment: 183 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Anemia, Iron Deficiency, Hyperphosphatemia, Renal Insufficiency, Chronic, Renal Anemia, Disease Progression, Cardiovascular, Iron
Interventions: Ferric Citrate 1 GM Oral Tablet [AURYXIA], Placebo; Drug
Lead sponsor: USRC Kidney Research; Network
Eligibility: 18 Years and older
Enrollment: 289 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 23
States / cities: Pine Bluff, Arkansas • Chula Vista, California • El Centro, California + 16 more

Conditions: Chronic Kidney Failure
Interventions: Fermagate, Placebo; Drug
Lead sponsor: Ineos Healthcare Limited; Industry
Eligibility: 18 Years and older
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 4
States / cities: Pine Bluff, Arkansas • Stuttgart, Arkansas • Charlotte, North Carolina

Conditions: Prostate Cancer
Interventions: NanoTherm Ablation; Device
Lead sponsor: MagForce USA; Industry
Eligibility: 40 Years to 85 Years · Male only
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 4
States / cities: Tampa, Florida • Austin, Texas • San Antonio, Texas + 1 more

Conditions: Infant Mortality, Preterm Birth, Low Birth Weight, Neonatal Mortality, Perinatal Mortality
Interventions: Iron (27 mg) - folic acid (600 ug), Multiple micronutrient; Dietary Supplement
Lead sponsor: Johns Hopkins Bloomberg School of Public Health; Other
Eligibility: 12 Years to 45 Years · Female only
Enrollment: 44,567 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Anemia, Iron Deficiency
Interventions: Ferric maltol capsule, Ferric maltol suspension; Drug
Lead sponsor: Shield Therapeutics; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Energy
Interventions: Heart & Soil Lifeblood; Dietary Supplement
Lead sponsor: Efforia, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Anemia, Cardiovascular Disease
Interventions: EPO, Feraheme; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 80 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 2
States / cities: Dallas, Texas

Conditions: Anemia
Interventions: Sodium ferric gluconate, ferrous sulfate, standard of care; Drug
Lead sponsor: Watson Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 32
States / cities: Bakersfield, California • Chula Vista, California • Long Beach, California + 29 more

Conditions: Iron Deficiency Anemia Treatment, Iron-deficiency, Iron Deficiency Anemia Due to Blood Loss, Iron Deficiency Anemia
Interventions: Packed red blood cells, Intravenous drug; Biological · Drug
Lead sponsor: Texas Tech University Health Sciences Center, El Paso; Other
Eligibility: 18 Years to 80 Years
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: El Paso, Texas

Conditions: Iron Deficiency Anemia
Interventions: Ferumoxytol, Saline, Ferrous sulfate tablets, Vitamin C; Drug
Lead sponsor: Auerbach Hematology Oncology Associates P C; Other
Eligibility: 18 Years and older
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Cystic Fibrosis, Anemia, Iron-Deficiency
Interventions: Ferrous sulfate 325mg, Placebo; Drug
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 2
States / cities: Portland, Maine • Lebanon, New Hampshire

Conditions: Anemia
Interventions: Biotin RBC survival; Drug
Lead sponsor: National Institute on Aging (NIA); NIH
Eligibility: 18 Years and older
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Iron Deficiency (ID), Heart Failure, Heart Failure and Reduced Ejection Fraction, Heart Failure and Mildly Reduced Ejection Fraction
Interventions: Notification Group, No Notification Group; Other
Lead sponsor: Kaiser Permanente; Other
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Pleasanton, California

Conditions: Adult Brain Glioblastoma
Interventions: Gadolinium, Ferumoxytol Non-Stoichiometric Magnetite, Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging, Diffusion Weighted Imaging, MRI-Based Angiogram; Drug · Other
Lead sponsor: OHSU Knight Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2014
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Spinal Cord Injury
Interventions: Not listed
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 18 Years to 90 Years · Male only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: SAH, Dementia
Interventions: Deferiprone pill, placebo, Montreal Cognitive Assessment; Drug · Behavioral
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 2
States / cities: Iowa City, Iowa • Durham, North Carolina

Conditions: Stroke, Intracranial Atherosclerosis
Interventions: Ferumoxytol Injectable Product; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Chronic Kidney Disease; Iron Deficiency Anemia
Interventions: Ferumoxytol, Iron sucrose; Drug
Lead sponsor: AMAG Pharmaceuticals, Inc.; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 129 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2026
U.S. locations: 8
States / cities: Hollywood, Florida • Detroit, Michigan • Kansas City, Missouri + 5 more

Conditions: Renal Failure Chronic Requiring Hemodialysis
Interventions: Soluble Ferric Pyrophosphate (SFP), Standard dialysate; Drug · Device
Lead sponsor: Rockwell Medical Technologies, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 305 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 45
States / cities: Bakersfield, California • Chula Vista, California • Cudahy, California + 37 more

Conditions: Iron Overload, Hereditary Hemochromatosis
Interventions: Deferasirox (ICL670); Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 9
States / cities: Long Beach, California • Farmington, Connecticut • Detroit, Michigan + 6 more

Search by objective public record fields.

Incidence of Hypophosphatemia After Treatment With Iron Isomaltoside/Ferric Derisomaltose vs Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia

Impact of Two Iron Formulations on Iron Biomarkers and Quality of Life

Pharmacokinetics of Triferic (Ferric Pyrophosphate Citrate) Administered Intravenously to Healthy Adult Volunteers

Iron Supplementation and Intestinal Health

Ferric Citrate for the Prevention of Renal Failure in Adults With Advanced Chronic Kidney Disease

Efficacy and Safety Study of Magnesium Iron Hydroxycarbonate for the Reduction of High Blood Phosphate in Hemodialysis Patients

Study of Focal Ablation of the Prostate With NanoTherm® Therapy System for Intermediate-Risk Prostate Cancer

Antenatal Micronutrient Supplementation and Infant Survival

Four-Way Crossover Study to Compare Ferric Maltol Capsules and Oral Suspension in Healthy Volunteers

Evaluating Heart & Soil's Lifeblood on Iron and Energy Levels

Active Preoperative Anemia Management in Patients Undergoing Cardiac Surgery

Effect of Iron Therapy as an Adjunct to Epoetin Alfa in the Anemia of Cancer Chemotherapy

IV Iron Versus Standard Treatment for Iron Deficiency Anemia in the Emergency Department

Trial of IV vs Oral Iron Treatment of Iron Deficiency Anemia in the Post-Operative Bariatric Surgical Patient

Does a Daily Iron Tablet Improve Anemia in Cystic Fibrosis

Mechanisms Accounting for Unexplained Anemia in the Elderly

Infusing Needed Iron to Target Insufficiency in Adults Treated for Evidence of Heart Failure

MRI Study With Ferumoxytol in Assessing Early Response in Patients With Glioblastoma Multiforme Receiving Temozolomide and Radiation Therapy

Iron & Vitamin C Study

Ferritin and Iron Burden in SAH sIRB

Treatment Targets for Inflamed Intracranial Atherosclerosis on Vessel Wall MRI

A Study to Evaluate the Safety (Compared to Iron Sucrose), Efficacy and Pharmacokinetics of Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects With Chronic Kidney Disease (CKD)

Continuous Soluble Ferric Pyrophosphate (SFP) Iron Delivery Via Dialysate in Hemodialysis Patients

Safety and Efficacy of Deferasirox (ICL670) in Patients With Iron Overload Resulting From Hereditary Hemochromatosis